The (important) role of the pharmacist in the handling of COPD

Table of Contents

The (important) role of the pharmacist in the handling of COPD

The Emerging Health System

Practice Level Strategies for Clinical Pharmacy-Oakbrook ‘98

Truths and/or Realities

Practice Level Strategies for Clinical Pharmacy- Oakbrook ‘98

Preparation for Health Care Team Outcomes Management

Necessary Coursework for the Future Pharmacy Practitioner

Compared to what we train as BS Pharmacists, Pharm Ds Must have:

Antibiotic Strategies in Hospitals

Roles in Therapeutic Optimization

Missions of The Clinical Pharmacokinetics Laboratory

Informatics in Action

Computer Assisted Outcomes Management

Problem Detection and Intervention to Optimize Care

Clinical Specialist Pharmacists

Still True

Transitions

Practical Approaches for Implementation of Pharmacodynamic Studies into Clinical Practice

Predominant Respiratory Tract Pathogens

Outpatient clinical studies in respiratory tract infections

Impact of limited clinical data and increasing pathogen resistance on choice of antibacterial therapy

PPT Slide

Evaluating antibiotic efficacy using pharmacokinetics and pharmacodynamics

PPT Slide

MIC50 and MIC90 unimodal population

MIC50 and MIC90 bimodal population

Pharmacokinetic Parameters

Patterns of Antimicrobial Activity

Relationship between PK/PD parameters and efficacy for cefotaxime against Klebsiella pneumoniae in a murine pneumonia model

Time above MICCorrelation of serum pharmacokinetics with MIC (susceptibility) of an organism

Time Above MIC: ?-Lactams

Relationship between Time above MIC and efficacy in animal infection models infected with S. pneumoniae

Time above MIC for ?-lactams

PPT Slide

24-hr AUC/MIC and Peak/MIC RatiosCorrelation of serum pharmacokinetics with MIC (susceptibility) of an organism

Relationship between 24 Hr AUC/MIC and mortality for fluoroquinolones against S. pneumoniae in immunocompetent animals

Relationship between 24 Hr AUC/MIC and mortality for fluoroquinolones against Gram-negative bacilli in immunocompromised animals

Predictors of Bacterial Eradication: Pharmacokinetic/Pharmacodynamic profiles

Pharmacokinetics of Continuous and Intermittent Ceftazidime in Intensive Care Unit Patients With Nosocomial Pneumonia

Steady-state Ceftazidime Serum Concentrations

Pharmacokinetic Parameters of Ceftazidime 2 g IV q8h and 3 g Cl over 24 Hours in Patients With Normal Renal Function

PPT Slide

Calculated Steady-state Concentrations of b-Lactams Administered by Continuous Infusion to Subjects With Normal Renal Function

Pharmacodynamic Approach for Ceftazidime Treatment of AECB (I)

Pharmacodynamic Approach for Ceftazidime Treatment of AECB (II)

PPT Slide

PPT Slide

PPT Slide

PPT Slide

Pharmacodynamic Approach for Ceftazidime Treatment of AECB (III)

Implementation of PD Approach in Clinical Practice

PPT Slide

Email: tulkens@facm.ucl.ac.be

Home Page: http://www.gsk-chair-infectious-diseases.be

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of the organisers of the GSK-Chair of Infectious Diseases